A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo - PubMed (original) (raw)
doi: 10.1038/nchembio.96. Epub 2008 Jun 29.
Affiliations
- PMID: 18587388
- DOI: 10.1038/nchembio.96
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Scott A Yuzwa et al. Nat Chem Biol. 2008 Aug.
Abstract
Pathological hyperphosphorylation of the microtubule-associated protein tau is characteristic of Alzheimer's disease (AD) and the associated tauopathies. The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and reductions in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain. We describe the rational design and synthesis of such an inhibitor (thiamet-G, K(i) = 21 nM; 1) of human O-GlcNAcase. Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathologically relevant sites including Thr231 and Ser396. Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo. We anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathological hyperphosphorylation of tau in AD.
Comment in
- Turning down tau phosphorylation.
Fischer PM. Fischer PM. Nat Chem Biol. 2008 Aug;4(8):448-9. doi: 10.1038/nchembio0808-448. Nat Chem Biol. 2008. PMID: 18641620 Review.
Similar articles
- Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
Yu Y, Zhang L, Li X, Run X, Liang Z, Li Y, Liu Y, Lee MH, Grundke-Iqbal I, Iqbal K, Vocadlo DJ, Liu F, Gong CX. Yu Y, et al. PLoS One. 2012;7(4):e35277. doi: 10.1371/journal.pone.0035277. Epub 2012 Apr 19. PLoS One. 2012. PMID: 22536363 Free PMC article. - MK-8719, a Novel and Selective _O_-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy.
Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, Terracina G, Lee J, Hong KK, Lu SX, Hyde L, Chen SC, Kinsley D, Melchor JP, Rubins DJ, Meng X, Hostetler E, Sur C, Zhang L, Schachter JB, Hess JF, Selnick HG, Vocadlo DJ, McEachern EJ, Uslaner JM, Duffy JL, Smith SM. Wang X, et al. J Pharmacol Exp Ther. 2020 Aug;374(2):252-263. doi: 10.1124/jpet.120.266122. Epub 2020 Jun 3. J Pharmacol Exp Ther. 2020. PMID: 32493725 - Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB, Wang X, Song L, Butts BD, Grotz D, Hargreaves R, Fred Hess J, Hong KK, Huang CR, Hyde L, Laverty M, Lee J, Levitan D, Lu SX, Maguire M, Mahadomrongkul V, McEachern EJ, Ouyang X, Rosahl TW, Selnick H, Stanton M, Terracina G, Vocadlo DJ, Wang G, Duffy JL, Parker EM, Zhang L. Hastings NB, et al. Mol Neurodegener. 2017 May 18;12(1):39. doi: 10.1186/s13024-017-0181-0. Mol Neurodegener. 2017. PMID: 28521765 Free PMC article. - O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P. Bartolomé-Nebreda JM, et al. Expert Opin Ther Pat. 2021 Dec;31(12):1117-1154. doi: 10.1080/13543776.2021.1947242. Epub 2021 Jul 8. Expert Opin Ther Pat. 2021. PMID: 34176417 Review. - O-GlcNAc modification and the tauopathies: insights from chemical biology.
Yuzwa SA, Vocadlo DJ. Yuzwa SA, et al. Curr Alzheimer Res. 2009 Oct;6(5):451-4. doi: 10.2174/156720509789207967. Curr Alzheimer Res. 2009. PMID: 19874270 Review.
Cited by
- Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis.
Tarrant MK, Rho HS, Xie Z, Jiang YL, Gross C, Culhane JC, Yan G, Qian J, Ichikawa Y, Matsuoka T, Zachara N, Etzkorn FA, Hart GW, Jeong JS, Blackshaw S, Zhu H, Cole PA. Tarrant MK, et al. Nat Chem Biol. 2012 Jan 22;8(3):262-9. doi: 10.1038/nchembio.771. Nat Chem Biol. 2012. PMID: 22267120 Free PMC article. - Protein O-GlcNAcylation Promotes Trophoblast Differentiation at Implantation.
Ruane PT, Tan CMJ, Adlam DJ, Kimber SJ, Brison DR, Aplin JD, Westwood M. Ruane PT, et al. Cells. 2020 Oct 6;9(10):2246. doi: 10.3390/cells9102246. Cells. 2020. PMID: 33036308 Free PMC article. - Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds.
Dorfmueller HC, van Aalten DM. Dorfmueller HC, et al. FEBS Lett. 2010 Feb 19;584(4):694-700. doi: 10.1016/j.febslet.2009.12.020. Epub 2009 Dec 16. FEBS Lett. 2010. PMID: 20026047 Free PMC article. - Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.
Austad SN, Ballinger S, Buford TW, Carter CS, Smith DL Jr, Darley-Usmar V, Zhang J. Austad SN, et al. Acta Pharm Sin B. 2022 Feb;12(2):511-531. doi: 10.1016/j.apsb.2021.06.014. Epub 2021 Jun 30. Acta Pharm Sin B. 2022. PMID: 35256932 Free PMC article. Review. - The role of tau kinases in Alzheimer's disease.
Dolan PJ, Johnson GV. Dolan PJ, et al. Curr Opin Drug Discov Devel. 2010 Sep;13(5):595-603. Curr Opin Drug Discov Devel. 2010. PMID: 20812151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases